electroCore, Inc. (NASDAQ:ECOR - Get Free Report) was the recipient of a significant increase in short interest in October. As of October 31st, there was short interest totalling 43,000 shares, an increase of 64.1% from the October 15th total of 26,200 shares. Based on an average daily trading volume, of 50,200 shares, the short-interest ratio is currently 0.9 days. Currently, 0.8% of the shares of the stock are sold short.
Institutional Trading of electroCore
An institutional investor recently raised its position in electroCore stock. Renaissance Technologies LLC raised its holdings in electroCore, Inc. (NASDAQ:ECOR - Free Report) by 3.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 68,786 shares of the company's stock after purchasing an additional 2,270 shares during the period. Renaissance Technologies LLC owned 1.15% of electroCore worth $442,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 26.74% of the company's stock.
electroCore Stock Performance
ECOR stock traded up $0.20 during trading on Thursday, reaching $13.60. 288,916 shares of the company were exchanged, compared to its average volume of 26,073. The company has a market cap of $87.68 million, a P/E ratio of -5.18 and a beta of 0.56. electroCore has a 52-week low of $5.02 and a 52-week high of $14.20. The stock's 50 day moving average price is $8.64 and its 200 day moving average price is $7.14.
electroCore Company Profile
(
Get Free Report)
electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
See Also
Before you consider electroCore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and electroCore wasn't on the list.
While electroCore currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
